Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Joel Schor

Bluefield, WV Medical Doctor

NPI 1003866997 CMS profile 181770

1027 Frederick St, Bluefield, WV 24701

Open in the dashboard

General payments

$8,436

528 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Joel Schor of Bluefield, WV is reported in the CMS Open Payments database as having received $8,436 across 528 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,292 69
2021 General $2,983 183
2020 General $2,200 135
2019 General $1,961 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joel Schor
  • West Virginia median
  • Middle half of West Virginia
  • National median

In program year 2025, general payments to Joel Schor were reported at $0. Among 5,795 West Virginia profiles paid that year, the median was $155 and the middle half received between $45 and $520.

Show as a table
Year Joel Schor West Virginia median Middle half National median
2019 $1,961 $145 $43–$559 $163
2020 $2,200 $105 $32–$362 $114
2021 $2,983 $124 $35–$430 $132
2022 $1,292 $134 $41–$475 $149
2023 $0 $144 $42–$508 $160
2024 $0 $146 $45–$531 $164
2025 $0 $155 $45–$520 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. E.R. Squibb & Sons, L.L.C. $871 61 payments
  2. Novartis Pharmaceuticals Corporation $869 49 payments
  3. Janssen Biotech, Inc. $858 59 payments
  4. Merck Sharp & Dohme Corporation $594 40 payments
  5. AstraZeneca Pharmaceuticals LP $558 28 payments
  6. Pfizer Inc. $425 28 payments
  7. Astellas Pharma US Inc $402 17 payments
  8. Seattle Genetics, Inc. $357 16 payments
  9. Janssen Pharmaceuticals, Inc $325 28 payments
  10. Genentech USA, Inc. $292 25 payments
  11. Other $2,885 177 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $7,837 517 payments
  2. Education $599 11 payments
Products named General payments · program years 2019–2022
  1. IMBRUVICA $718 54 payments
  2. OPDIVO $651 44 payments
  3. DARZALEX $625 47 payments
  4. KEYTRUDA $543 36 payments
  5. MEKINIST $391 19 payments
  6. XARELTO $325 28 payments
  7. TAFINLAR $322 16 payments
  8. XTANDI $271 15 payments
  9. XPOVIO $268 16 payments
  10. CALQUENCE $243 12 payments
  11. Other $5,993 388 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

528 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record